Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Thomas Jefferson University
This is an open-label expanded access program to make appropriately matched convalescent plasma available for the treatment of patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease. COVID-19 convalescent plasma will be obtained from the Jefferson Blood Bank and will meet all regulatory requirements for conventional plasma and FDA's additional considerations for COVID-19 convalescent plasma (https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 years and older
Laboratory confirmed diagnosis of SARS-CoV-2
Admitted to an acute care facility for the treatment of COVID-19 complications
Informed consent provided by patient or legally authorized representative
Severe or life threatening COVID-19, or judged by the treating provider to be at high risk of progression to severe or life-threatening disease
Severe Disease defined as any of the following
Dyspnea
Respiratory rate \> 30/minute
Oxygen saturation \<94%
Partial pressure of arterial oxygen to fraction of inspired oxygen ratio \<300
Lung infiltrates \>50% within 24 to 48 hours
Life-threatening disease defined as any of the following
Respiratory failure
Septic shock
Multiple organ dysfunction or failure • Informed consent provided by patient or healthcare proxy
You may not be if
Receipt of pooled immunoglobulin in past 30 days
Contraindication to transfusion or history of prior reactions to transfusion blood products
Clareo Health | Convalescent Plasma for the Treatment of COVID-19
